Roche Holding stock: FDA authorizes cobas platform for testing
Published on 11/20/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDiagnostics Expansion Adds A New Test
- The FDA granted De Novo authorization for Roche's cobas pro i 601 platform with the Ionify Gabapentin assay.
- The system combines mass spectrometry with an automated workflow for routine clinical laboratories.
- An authorized change-control plan covers up to 22 additional Ionify assays, subject to future requirements.
Roche announced on Monday, November 16, that the U.S. Food and Drug Administration had granted De Novo authorization for its cobas pro i 601 platform with the Ionify Gabapentin assay. The company described the decision in a Roche announcement published on that date.
Mass Spectrometry Moves Into Routine Labs
The authorized platform is part of Roche's cobas Mass Spec solution. It combines the analytical capabilities of mass spectrometry with an automated and standardized workflow designed for routine clinical laboratories.
The Ionify Gabapentin assay adds therapeutic drug monitoring to Roche's U.S. diagnostic menu. The existing menu includes 25-Hydroxy Vitamin D total and steroid hormone testing assays such as estradiol and 17-Hydroxyprogesterone.
Future Menu Expansion Remains Conditional
Roche said the FDA-authorized Predetermined Change Control Plan covers the expansion of up to 22 additional Ionify assays on the platform. Those assays are not yet available and are expected to be introduced as the applicable requirements are met.
For investors, the authorization broadens Roche's diagnostics offering beyond medicines and supports a more automated approach to testing that has traditionally required specialized laboratory workflows. Commercial uptake and the timing of any additional assays remain key factors for the business outlook.
Roche Holding stock traded at 429.78 euros on Lang & Schwarz at 17:35 CET on Friday, November 20.
Roche Holding
- ISIN: CH1499059983
- Trading venue: Lang & Schwarz
- Quoted price: 429.78 euros at 17:35 CET on Friday, November 20, 2026
- Regulatory event: FDA De Novo authorization announced on November 16, 2026
Swiss equity developments are covered in Current market reports.
